MedPath

Transcutaneous vagus nerve stimulation to enhance exposure efficacy in public speaking anxiety

Conditions
Social anxiety disorder
Registration Number
NL-OMON20935
Lead Sponsor
eiden University Behandel en Expertise Centrum
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Pending
Sex
Not specified
Target Recruitment
52
Inclusion Criteria

In order to be eligible to participate in this study, a subject must meet all of the following criteria:
A. Between 18-70 years old
B. Social Anxiety Disorder (SAD) as established with a structured interview (MINI), and with speech anxiety as primary fear.
C. Self-reported SAD symptoms above clinical cut-off (score > 30 on the LSAS)

Exclusion Criteria

A potential subject who meets any of the following criteria will be excluded from participation in this study:
A. Prior non response to exposure therapy (i.c. speech exposure) for SAD symptoms, as defined by the patient’s report of receiving specific and regular exposure assignments as part of previous therapy.
B. Prior participation in tVNS research
C. Entry of patients with other mood or anxiety disorders will be permitted in order to increase accrual of a clinically relevant sample; however in cases where SAD is not judged to be the predominant disorder, participants will not be eligible.
D. Psychosis or delusion disorders (current or in the past)
E. Patients with significant suicidal ideations or who have enacted suicidal behaviors within 6 months prior to intake will be excluded from participation and referred for appropriate clinical intervention.
F. Mental retardation
G. Substance or alcohol dependence
H. Somatic illness (neurological and cardiac conditions)
I. Pregnancy or lactation
J. Antipsychotic medication
K. Participants that use antidepressants or benzodiazepines will not be excluded, but have to be on a stable dose for at least 6 weeks prior to enrollment.
L. Insufficient ability to speak and write Dutch

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Facilitation of extinction, as expressed by steeper slopes of SUDs decline during the first session in the tVNS condition.
Secondary Outcome Measures
NameTimeMethod
Enhanced retention of extinction memory, as expressed by lower mean SUD ratings during session 2 in the tVNS condition.
© Copyright 2025. All Rights Reserved by MedPath